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Abstract
Background: Inosine pranobex (Isoprinosine®) is an immunomodulatory drug approved in several countries for
the treatment of viral infections. This study compared the efficacy and safety of inosine pranobex versus placebo
in subjects with clinically diagnosed influenza-like illness, including subjects with laboratory-confirmed acute
respiratory viral infections. Subgroup analyses evaluated the efficacy of inosine pranobex compared to placebo
in otherwise healthy (without related ongoing disease) subjects that were less than 50 years of age and healthy
subjects that were at least 50 years of age. The effect of body mass index (BMI) was evaluated in subjects less
than 50 years of age.
Methods: A total of 463 subjects were randomly assigned to receive inosine pranobex (n = 231) or placebo
(n = 232) in this Phase 4, randomised, double-blind, multicentre study. The primary efficacy endpoint was time to
resolution of all influenza-like symptoms present at baseline to none. Safety was evaluated through analysis of
adverse events, vital signs, and physical examinations.
Results: The difference in time to resolution of all influenza-like symptoms between treatment groups was not
statistically significant but showed a faster improvement in subjects in the inosine pranobex group versus those
in the placebo group - Hazard Ratio = 1.175; (95 % CI: 0.806–1.714). P-value = 0.324. In the subgroup analysis for
subjects less than 50 years of age, statistically significant differences in time to resolution of influenza-like symptoms
that favoured the inosine pranobex group over the placebo group were observed in those without related ongoing
disease and those who were non-obese (BMI <30 kg/m2). The differences between the inosine pranobex and
placebo groups in subjects at least 50 years of age without related ongoing disease and in subjects less than
50 years of age who were obese (BMI ≥30 kg/m2) were not statistically significant. Inosine pranobex was generally
well tolerated, and no deaths were reported.
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Conclusions: The study results indicate the safety of inosine pranobex for the treatment of subjects with confirmed
acute respiratory viral infections and confirm the efficacy of inosine pranobex versus placebo in healthy non-obese
subjects less than 50 years of age with clinically diagnosed influenza-like illnesses.
Trial registration: EWO-ISO-2014/1, EudraCT 2014-001863-11; Date of registration: 29 APR 2014; Detail information
web link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001863-11/results
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Background
Acute respiratory infection is a serious infection that is
responsible for approximately 3.9 million deaths per year
and is one of the leading causes of morbidity and mor-
tality worldwide [1]. Acute respiratory infections are cat-
egorized as either upper or lower respiratory infections
and are caused by well-recognised viral pathogens, in-
cluding but not limited to influenza virus (types A and
B), parainfluenza virus, respiratory syncytial virus (RSV),
metapneumovirus (types A and B), coronavirus, rhino-
virus, enterovirus, reovirus, bocavirus, and adenovirus,
and bacterial pathogens, primarily Streptococcus pneu-
moniae and Haemophilus influenza [2, 3].
Influenza is an acute viral respiratory infection that af-
fects 5 % to 15 % of the global adult population per year
and results in approximately 0.25 to 0.5 million deaths
and 3 to 5 million cases of severe illness worldwide
annually [4, 5]. Influenza-like illnesses (ILI) are consid-
ered a subset of acute respiratory infections and result in
the sudden onset of symptoms such as fever (body
temperature greater than 38 °C), cough, and sore throat
in patients [5]. Physicians have difficulty with the treat-
ment of ILI because determining the aetiology is gener-
ally not possible solely on a clinical basis.
Current pharmacological interventions for the preven-
tion and treatment of respiratory viral infections are pri-
marily limited to vaccines and antivirals for influenza.
Available antiviral treatments for influenza infection are
M2 ion channel inhibitors (eg, amantadine and rimanta-
dine) and neuraminidase inhibitors (eg, oseltamivir and
zanamivir) [6]. If the infection is caused by bacterial
pathogens, treatment can involve antibiotics and also
medications that provide symptomatic relief. However,
in case of viral aetiology, only medication for symptom-
atic treatment can be provided. [7].
Vaccination for seasonal influenza remains one of the
standard approaches for prevention of the disease. How-
ever, immunisation rates for seasonal influenza remain
low in many European countries even though the influ-
enza vaccine is part of the national immunisation sched-
ule in these countries [8]. Moreover, the vaccination is
effective only when most of the circulating influenza vi-
ruses in a given season are similar to the viruses that
were included in the influenza vaccine. The vaccine does
not offer any clinical benefit against other pathogens
that circulate during a season [9].
Inappropriate use of antibiotics for the treatment of
acute respiratory infections has been observed during
winter months, even though the majority of infections
are caused by viral pathogens and are self-limiting.
This practice may result in side effects and the devel-
opment of antibiotic resistance in pathogens as well
as an increased cost burden for the healthcare system
[3, 10, 11].
Inosine pranobex (Isoprinosine®), a combination of the
p-acetamidobenzoate salt of N,N-dimethylamino-2-pro-
panol and inosine in a 3:1 molar ratio, is an immuno-
modulatory antiviral drug that has been licensed since
1971 in several countries worldwide for the treatment of
viral infections [2, 12]. Inosine pranobex stimulates a
nonspecific immune response that is independent of the
specific viral antigen responsible for the ILI. In clinical
studies, inosine pranobex has been shown to induce a type
1 T helper cell-type response in mitogen- or antigen-
activated cells, and this response initiates T-lymphocyte
maturation and differentiation and potentiates induced
lymphoproliferative responses (13–15). Similarly, the drug
modulates T-lymphocyte and natural killer cell cytotoxicity
and CD8+ suppressor and CD4 + -helper cell func-
tions and increases the number of immunoglobulin G
and complement surface markers (14, 15). Inosine
pranobex also increases cytokine interleukin (IL)-1
production and IL-2 production and upregulates the
expression of the IL-2 receptor in vitro [13, 14]. The
safety profile of inosine pranobex has been established
through clinical trials for several indications and popula-
tions [2, 14–16]. A rapid increase in the number of mono-
nuclear cells after the first dose of inosine pranobex was
observed in 75 % of the subjects, and this increase was
consistent with clinical observations of rapid resolution of
common cold symptoms [15, 17].
This Phase 4 study aimed to compare the efficacy and
safety of inosine pranobex with placebo in subjects with
laboratory-confirmed acute respiratory viral infections in
order to evaluate the clinical use of inosine pranobex for
the treatment of acute respiratory viral infections. The
Beran et al. BMC Infectious Diseases  (2016) 16:648 Page 2 of 10
primary efficacy endpoint was comparison between in-
osine pranobex and placebo groups in terms of the time
to resolution of all influenza-like symptoms present at
baseline to none. In a subgroup analysis of subjects with
clinically diagnosed ILI, the study further evaluated the
efficacy of inosine pranobex compared to placebo in
healthy (without related ongoing disease) subjects less
than 50 years of age and in those at least 50 years of age.
The study also evaluated the effect of body mass
index (BMI) in subjects who were less than 50 years
of age and were non-obese (BMI <30 kg/m2) or
obese (BMI ≥30 kg/m2). In addition, the study evalu-
ated the efficacy of inosine pranobex in subjects less
than 50 years of age for the time to resolution of all
influenza-like symptoms present at baseline to mild




This was a Phase 4, randomised, placebo-controlled,
double-blind, multicentre study in subjects with clinic-
ally diagnosed ILI, including subjects with laboratory-
confirmed acute respiratory viral infections due to
influenza A or B virus, RSV, adenovirus, or parainfluenza
virus 1 or 3. The study was conducted at 25 study sites
in the Czech Republic (14 study sites) and Slovakia (11
study sites), with enrolment occurring between Decem-
ber 2014 and April 2015, and the last subject visit was
on 03 June 2015. Detailed primary efficacy endpoints are
provided in the Additional file 1.
Inclusion criteria
Male and nonpregnant female subjects aged 18 to
75 years with a clinical diagnosis of ILI were included in
this study. Influenza-like illnesses were defined as an
oral temperature of at least 38 °C observed at the study
site with at least 1 respiratory symptom of cough, sore
throat, or nasal obstruction and at least 1 constitutional
symptom of fatigue, headache, myalgia, or feverishness.
The respiratory and constitutional symptoms were re-
quired to be considered by the subject as moderate or
severe in intensity (a score of more than 1 on the 4-
point influenza-like symptoms assessment scale). The
subjects were required to have experienced the onset of
ILI no more than 36 h prior to screening, where onset is
defined as the time when the subject experienced fever
and at least 1 respiratory symptom and at least 1 consti-
tutional symptom. The full inclusion criteria and
Influenza-Like Symptoms Assessment Scale are detailed
in the Additional file 1.
Exclusion criteria
Subjects were excluded from participation in this study if
they met any of the following criteria: had an immunosup-
pressive disorder or were receiving immunosuppressive
therapy; were undergoing treatment with xanthine oxidase
inhibitors or uricosuric agents or treatment with thiazide
or loop diuretics; had chronic renal dysfunction or severe
liver function impairment; were lactose intolerant; had
cancer in a nonremission stage; were undergoing
treatment with zidovudine; were pregnant or lactating/
breastfeeding; had received a dose of inosine pranobex,
oseltamivir, zanamivir, amantadine, or rimantadine during
this occurrence of ILI; or had been administered an inves-
tigational drug or investigational vaccine within 30 days
prior to screening. Detailed exclusion criteria are provided
in the Additional file 1.
Sample size calculation
A sample size of 258 subjects (129 subjects in each treat-
ment group) in the modified intent-to-treat (mITT) ana-
lysis set with a total of 430 randomly assigned subjects
was calculated using the log-rank test (inputting the me-
dian survival times). Sample size calculations were per-
formed using PASS software Version 12 (NCSS, LLC,
Kaysville, Utah, USA) and considered a statistical power
of 80 % to detect a clinically relevant difference between
3.5 days in the treatment group and 5 days in the pla-
cebo group. A 20 % dropout rate was also considered,
which meant that a final sample size of 206 subjects
(103 subjects in each treatment group) would be re-
quired for the study. However, because of the challenges
faced during enrolment, which included a late influenza
alert and an unexpectedly mild influenza season, the de-
cision was made to continue enrolment until 30 April
2015. A total of 463 subjects were randomly assigned,
and of these, only 137 subjects met the criteria for inclu-
sion in the mITT analysis set.
Statistical analysis
All analyses were conducted using SAS® software Ver-
sion 9.2 (SAS Institute Inc, Cary, North Carolina, USA).
All statistical tests were 2-sided hypothesis tests per-
formed with a 5 % level of significance, which resulted
in 95 % (2-sided) confidence intervals (CIs). No adjust-
ments for multiplicity were made. The hazard ratios
(HRs) and 95 % CIs were estimated using a proportional
hazards model (HR >1 indicated a benefit to inosine pra-
nobex compared with placebo). The safety analysis set
consisted of all subjects who received at least 1 dose of
any study drug. All analyses using the safety analysis set
grouped subjects according to the treatment that the
subjects had actually received. The mITT analysis set
consisted of all randomly assigned subjects who had a
positive laboratory confirmation of acute respiratory
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viral infection due to influenza A or B virus, RSV,
adenovirus, or parainfluenza virus 1 or 3. This set was
used for the primary and secondary efficacy analyses.
Detailed primary efficacy endpoints are provided in the
Additional file 1. All analyses using the mITT analysis
set grouped subjects according to the randomised
treatment. The intent-to-treat (ITT) analysis set in-
cluded all subjects who were randomly assigned to re-
ceive double-blinded study drug and was used for the
subgroup analyses.
Randomisation and blinding
On Day 1, eligible subjects were randomly assigned to
receive either inosine pranobex or placebo in a 1:1 allo-
cation ratio with no stratification. The active drug and
matching placebo tablets were provided in identical car-
tons that were identified with a kit number, such that all
study site staff and subjects remained blinded through-
out the study. Only personnel with access to the inter-
active web response system and clinical supplies were
unblinded and had access to the treatment assignments;
all other parties involved in the study were fully blinded.
Intervention
Inosine pranobex or placebo 500-mg tablets were self-
administered by the subjects for 7 days (2 tablets orally
3 times daily). The first dose was taken immediately after
randomisation at the study site, and the remaining doses
were to be self-administered at home. Doses were taken
approximately 8 h apart but consistent with the subject’s
lifestyle, ie, scheduling of dosing did not disturb the sub-
ject’s usual sleep patterns. The subjects were provided
with kits containing (randomised) medication sufficient
for 1 subject for 7 days of treatment. Subjects were
instructed to consume no more than 42 tablets for the
specified duration and were required to return the ex-
cess study drug tablets at the end-of-treatment (EOT)
visit. Adherence to study drug administration was good
and was monitored as part of the study.
Procedures
The total study duration was 21 days (±3 days) for each
subject and consisted of a 7-day dosing period (Day 1 to
Day 7), 1 day for the EOT visit (Day 8 + 1 day), and a
13-day follow-up period (Day 21 ± 3 days) after the EOT
visit. Prior to randomisation on Day 1, a nasopharyngeal
swab sample was collected to test for the presence of in-
fluenza A or B virus, RSV, adenovirus, and parainfluenza
virus 1 or 3 using the appropriate polymerase chain re-
action analyses. The results were used to identify the
subjects to be included in the mITT set and consequen-
tially identify the subjects to be included in the primary
endpoint analysis. A detailed procedure for the study
visits is included in the Additional file 1.
Efficacy and subgroup analysis
The primary efficacy endpoint was the time to resolution
of all influenza-like symptoms present at baseline to
none (ie, a score of 0, defined as the complete absence
of symptoms, on the influenza-like symptoms assess-
ment scale [details provided in Additional file 1]). The
secondary endpoints included time to resolution of re-
spiratory symptoms (cough, sore throat, and nasal ob-
struction); time to absence of fever (oral temperature of
≤37.5 °C for at least 2 consecutive readings that were at
least 12 h apart); time to resumption of normal activity
(ie, score of 0 on daily activities assessment scale); and
frequency of viral respiratory infection complications,
defined as hospitalisation, death due to ILI or complica-
tions of ILI, or requirement of antibiotic treatment for
secondary bacterial infection.
A subgroup analysis was conducted for time to reso-
lution of all influenza-like symptoms present at baseline
to none in subjects with clinically diagnosed ILI. This
was conducted in subjects less than 50 years of age and
subjects at least 50 years of age without related ongoing
disease (related ongoing disease was any medical condi-
tion with the preferred terms of asthma, bronchitis,
chronic bronchitis, or chemical bronchitis that was
ongoing at the start of the study). In addition, an
analysis was conducted in subjects less than 50 years
of age who were non-obese (BMI <30 kg/m2) or
obese (BMI ≥30 kg/m2). An additional analysis was
conducted for time to resolution of all influenza-like
symptoms to mild or none for subjects less than
50 years of age.
Safety analysis
Safety was evaluated during the study through analysis
of adverse events (AEs), vital signs, and physical
examinations.
Bioethical issues
The study was performed in accordance with ethical
principles that have their origin in the Declaration of
Helsinki, International Council for Harmonization E6
(R1), and all applicable regulations. Study was approved
before study start by two Multicentre Ethics Committees
(MEC). One MEC in the University hospital Brno ap-
proved study for all study centres in the Czech Republic
and the second one MEC of Košice Regional Office ap-
proved study for all study centres in Slovakia. All poten-
tial subjects signed an informed consent form prior to
randomisation on Day 1 before any study-related proce-
dures were performed.
Results
The study included a total of 463 subjects who were
randomly assigned to receive either inosine pranobex
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(n = 231) or placebo (n = 232), and 98.5 % of subjects
completed the study (Fig. 1 – Flow chart). There were
7 subjects who discontinued the study; the reasons
included protocol noncompliance (n = 2), AEs (n = 2;
rhinopharyngitis and pleuropneumonia), and with-
drawal of consent (n = 2). Overall, 137 subjects
(29.6 %) had positive nasopharyngeal swab test results
and were included in the mITT analysis set (inosine
pranobex, n = 71; placebo, n = 66).
Demographic and baseline characteristics
The details of the demographic and baseline characteris-
tics are presented in the Additional file 1. The demo-
graphic characteristics were similar between the 2
treatment groups. The overall mean age was 41.9 years,
and the overall mean BMI was 26.450 kg/m2 (range:
12.07 to 45.11 kg/m2). The majority of subjects in this
study were less than 65 years of age. At baseline, most of
the subjects presented with at least 1 influenza-like
symptom (cough, sore throat, nasal obstruction, fatigue,
headache, myalgia, or feverishness) with a score of 1, 2,
or 3 in severity. Medical histories were reported for 172
subjects (74.5 %) in the inosine pranobex treatment
group and 178 subjects (76.7 %) in the placebo group,
and the most commonly reported medical histories were
vascular disorders and surgical and medical procedures.
Medical histories of gastrointestinal disorders (10.8 % in
the inosine pranobex group and 11.2 % in the placebo
Fig. 1 Flow-chart of enrolment, placement in treatment and placebo arms, division into the different subgroups and mITT and ITT analysis sets
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group) and hepatobiliary disorders (10.4 % in the inosine
pranobex group and 11.6 % in placebo group) were also
reported.
Compliance
Overall, the mean reported dose compliance was high,
and it was similar between treatment groups (97 % in
each treatment group). In the majority of subjects in
both treatment groups, dose compliance ranged from
80 to 120 % (inosine pranobex, n = 217 [94.8 %]; pla-
cebo, n = 220 [93 %]).
Efficacy analysis
The difference in time to resolution of all influenza-like
symptoms between treatment groups was not statisti-
cally significant but showed a trend towards improve-
ment in subjects in the inosine pranobex group
compared with subjects in the placebo group (HR: 1.175;
95 % CI: 0.806, 1.714; p = 0.324) (Fig. 2). A substantial
decrease in the proportion of subjects with all influenza-
like symptoms was observed in the inosine pranobex
group after 9 days while a decrease to similar propor-
tions occurred only after 11 days for subjects in the
placebo group.
The differences in time to resolution for the sec-
ondary endpoints also showed a similar trend to-
wards improvement for subjects in the inosine
pranobex group compared with subjects in the pla-
cebo group, but these secondary endpoint differences
were not significant. The detailed results are pro-
vided in the Additional file 1.
Subgroup analysis
In the subgroup analysis, for subjects less than 50 years
of age without related ongoing disease, the difference in
time to resolution of all influenza-like symptoms be-
tween treatment groups was statistically significant (p =
0.050) and showed faster improvement in subjects in the
inosine pranobex group compared with subjects in the
placebo group (HR: 1.234; 95 % CI: 0.969, 1.571) (Fig. 3
and Table 1). However, for subjects at least 50 years of
age without related ongoing disease, the difference in
time to resolution of all influenza-like symptoms be-
tween treatment groups was not statistically significant
(HR:0.887; 95 % CI: 0.0.604, 1.303; p = 0.488).
For non-obese (BMI <30 kg/m2) subjects less than
50 years of age, the difference in time to resolution of all
influenza-like symptoms between treatment groups was
statistically significant (p = 0.018) and showed a faster
improvement in subjects in the inosine pranobex group
compared with subjects in the placebo group (HR: 1.307;
95 % CI: 1.010, 1.691). However, for obese (BMI ≥30 kg/
m2) subjects less than 50 years of age, the difference in
time to resolution of all influenza-like symptoms
Fig. 2 Kaplan-Meier Plot for Time to Resolution of All Influenza-Like Symptoms. (mITT Analysis Set). mITT =modified intent-to treat analysis set.
Note: Time to resolution was the total number of days from randomisation to the first instance at which all influenza-like symptoms had a score
of 0 (date of resolution of all influenza-like symptoms minus the date of randomisation + 1)
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between treatment groups was not statistically signifi-
cant (HR: 0.782; 95 % CI: 0.429, 1.426; p = 0.370).
In subjects less than 50 years of age, the difference in
time to resolution of all influenza-like symptoms to mild
or none between treatment groups was statistically sig-
nificant (p = 0.009) and showed a faster improvement in
subjects in the inosine pranobex group compared
with subjects in the placebo group (HR: 1.298; 95 %
CI: 1.035, 1.627).
Safety analysis
The proportion of subjects experiencing treatment-
emergent AEs (TEAEs) and the number of TEAEs were
lower in the inosine pranobex group (39 subjects [17.0 %],
55 TEAEs) than in the placebo group (48 subjects [20.4 %],
72 TEAEs). The most common TEAEs (reported in more
than 3 subjects in either treatment group) were bacterial
superinfection (inosine pranobex, n = 10 [4.4 %]; placebo,
n = 2 [0.9 %]) and diarrhoea (inosine pranobex, n = 2
[0.9 %]; placebo, n = 7 [3.0 %]). No other TEAE was re-
ported in more than 3 subjects in either treatment group.
The majority of TEAEs were mild or moderate in
severity and were unrelated to study drug, in the
opinion of the investigator. Overall, 4 severe TEAEs
were reported in 3 subjects (0.6 %). Severe TEAEs of
rhinopharyngitis, maxillary sinusitis, and vertebrogenic
pain syndrome were reported in 1 subject (0.4 %)
each in the inosine pranobex group, and the severe
TEAE of pleuropneumonia was reported in 1 subject
(0.4 %) in the placebo group. No deaths were re-
ported during the study.
Overall, 6 subjects (2.6 %) in the inosine pranobex
group and 7 subjects (3.0 %) in the placebo group expe-
rienced TEAEs that led to study drug discontinuation.
Three treatment-emergent serious AEs (SAEs) were re-
ported in 2 subjects (0.4 %). Severe rhinopharyngitis and
severe vertebrogenic syndrome were reported in 1 sub-
ject in the inosine pranobex group, and 1 subject in the
placebo group reported severe pleuropneumonia. These
SAEs resulted in permanent discontinuation of the study
drug and discontinuation of both subjects from the
study. All SAEs resolved, and none of the SAEs in the
opinion of the investigator were related to the study
drug.
The mean changes in vital sign and physical examin-
ation values from baseline were small, and no clinically
Fig. 3 Time to Resolution of Influenza-Like Symptoms in Subjects <50 Years Without Related Ongoing Disease. Analysis carried out in the intent-to
treat analysis set. Note: Time to resolution was the total number of days from randomisation to the first instance at which all influenza-like symptoms
had a score of 0 (date of resolution of all influenza-like symptoms minus the date of randomisation + 1)
Table 1 Time to resolution of all influenza-like symptoms
between treatment groups
Group for analysis Hazard ratio (HR) 95 % CI P-value
Age Group: <50 and BMI <30 1.307 1.010–1.691 0.018
Age Group: <50 and BMI ≥30 0.782 0.429–1.426 0.370
Age Group: ≥50 and BMI <30 0.838 0.534–1.316 0.383
Age Group: ≥50 and BMI ≥30 0.879 0.445–1.736 0.683
Age Group: <50 and resolution
of symptoms to "mild" or "none"
1.298 1.035–1.627 0.009
The "bold data" are statisticly significant
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significant trends were observed between treatment
groups. No pregnancies were reported during the study.
Discussion
This was a Phase 4, randomised, placebo-controlled,
double-blind, multicentre study that evaluated the effi-
cacy of inosine pranobex in subjects with clinically diag-
nosed ILI, including subjects with laboratory-confirmed
acute respiratory viral infections due to influenza A or B
virus, RSV, adenovirus, or parainfluenza virus 1 or 3.
The study also evaluated the efficacy of inosine pranobex
in subgroups of subjects less than 50 years of age who
were without related diseases (such as asthma, bron-
chitis, chronic bronchitis, and chemical bronchitis) and
who were non-obese (BMI <30 kg/m2) or obese (BMI
≥30 kg/m2) as well as a subgroup of subjects at least
50 years of age without related ongoing disease. In
addition, a subgroup analysis was conducted in subjects
less than 50 years of age for time to resolution of all
influenza-like symptoms to mild or none.
In the current study, the analysis of the primary end-
point of time to resolution of all influenza-like symp-
toms showed a faster improvement in subjects treated
with inosine pranobex compared with subjects adminis-
tered placebo, although the difference between treat-
ment groups did not reach the threshold of statistical
significance. The results were similar for the secondary
efficacy endpoints of time to resolution of respiratory
symptoms (cough, sore throat, and nasal obstruction),
time to absence of fever, and time to resumption of nor-
mal activity. The difference in the occurrence of viral
respiratory infection complications between treatment
groups was not statistically significant.
Immunosenescence, ie, the age-related decline of the
immune system, and obesity play an important role in
the efficacy of the immune response to pathogens [18,
19]. Older subjects show a diminished immune response
to pathogens, which increases their risk for severe infec-
tion and compromises their ability to adequately combat
viral infections. This phenomenon was observed with
split-virus influenza vaccines; a low response to the vac-
cine was observed in older adults, whereas the vaccine
was effective in younger subjects. This low response re-
sulted in increased susceptibility to influenza and associ-
ated complications in older adults compared to younger
adults who typically benefit from a higher response [20,
21]. Obesity has also been identified as an independent
risk factor for increased susceptibility to influenza virus
infection; this susceptibility results from diminished
CD4+ and CD8+ T-cell responses and lower influenza
vaccine antibody levels [19, 22, 23]. Obesity may also in-
crease the risk of pneumonia or other infections by
restricting lung volume [24]. Immunosenescence and
obesity can bias efficacy studies because of the impaired
response of the immune system to pathogens, as the risk
of complications is increased in such individuals.
In the subgroup analysis of the current study, in sub-
jects less than 50 years of age who were without related
ongoing disease and in those less than 50 years of age
who were non-obese (BMI <30 kg/m2), statistically sig-
nificant differences in time to resolution of influenza-
like symptoms favoured the inosine pranobex group over
the placebo group. Statistically significant differences
were not observed between the inosine pranobex and
placebo groups in subjects at least 50 years of age with-
out related ongoing disease or in subjects less than
50 years of age who were obese (BMI ≥30 kg/m2). Thus,
the efficacy of inosine pranobex was improved in non-
obese subjects compared with obese subjects, probably
because the immune system in the former is more cap-
able of defending against pathogens and is not negatively
affected by obesity-related complications. Older patients
have a decreased immune response to pathogens as a re-
sult of immunosenescence; therefore, they may take lon-
ger to recover from illnesses such as influenza and anti-
influenza drugs may not be as effective. In an additional
analysis, in subjects less than 50 years of age, statistically
significant differences in time to resolution of influenza-
like symptoms to mild or none favoured the inosine pra-
nobex group over the placebo group, thus indicating that
the improvement of symptoms was better with inosine
pranobex than placebo in this subset of subjects (HR:
1.298; 95 % CI: 1.035, 1.627).
A substantial decrease in the proportion of subjects
with all influenza-like symptoms was observed in the
inosine pranobex group after 9 days while a decrease
to similar proportions occurred only after 11 days for
subjects in the placebo group. This difference could be
a result of the time necessary for activation of the im-
mune system, as inosine pranobex acts indirectly by
stimulating the immune system and does not directly
attenuate the symptoms. This result is also consistent
with the results observed in a study in healthy volun-
teers in which inosine pranobex showed immunomo-
dulating properties through an increase in serum
levels of interferon-γ, IL-2, IL-10, and tumour necrosis
factor-α from 7 to 10 days [13].
The approved dose and treatment duration of inosine
pranobex (two 500-mg tablets orally 3 times daily) were
used in this study, and the administered treatment did
not vary according to weight or symptom duration.
From the subgroup analysis, the posology of inosine
pranobex (3 g/day orally) in this study is most suit-
able for subjects less than 50 years of age without re-
lated ongoing disease and subjects less than 50 years
of age who were non-obese (BMI <30 kg/m2). For
certain subjects, such as those at least 50 years of age
and those who are obese, different dosing strategies
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could be more appropriate; varying the dosing regi-
men requires further evaluation.
The use of a placebo-only group in this study was jus-
tified because ILI is generally mild and self-limiting and
no other treatments are approved for acute respiratory
viral infections other than influenza. In addition, the use
of influenza-specific antivirals (neuraminidase inhibitors
or amantadine) is not a component of routine medical
management of ILI in many countries, including the
countries in which the study was conducted.
Performing a high-quality efficacy trial for ILI is chal-
lenging because of epidemiologic considerations from
the influenza outbreak period; the influenza season can-
not be predicted in advance and can vary from year to
year [25]. Furthermore, the enrolment of subjects with
symptoms that have been present for less than 36 h is
necessary, as the first 36 h is the period of maximal viral
replication and antiviral medication is expected to have
the most benefit during this time. The current study was
anticipated to be performed in 1 influenza season in the
Northern Hemisphere, between 01 October 2014 and 30
April 2015, and enrol the required number of subjects in
each group during this timeframe. However, enrolment
was challenging, as it could not be commenced because
of a low attack rate and was only started after a late alert
was issued by national public health authorities in the
first week of December 2014 regarding the statistically
higher incidence of acute respiratory viral infections. A
low density of circulating viruses was present until the
end of January 2015, which resulted in the enrolment of
subjects until 30 April 2015 in order to maximize the
number of completed subjects. Approximately 60 % of
the randomised subjects were expected to have a posi-
tive laboratory confirmation of acute respiratory tract in-
fection. However, only 137 subjects met the criteria for
inclusion in the mITT analysis set, which was 121 sub-
jects fewer than the 258 subjects expected. The effects
of the absence of a significant influenza outbreak ad-
versely affected the statistical power, thus reducing the
power of the study, which could potentially explain the
lack of statistical significance for the primary and sec-
ondary efficacy endpoints.
A slightly longer duration of treatment or a different
dosing strategy may have influenced the observed effi-
cacy of inosine pranobex, as proof of therapeutic effect
requires a high attack rate, ie, a higher number of sick
patients during one influenza season. The attack rate is
difficult to predict, and studies, which will adjust the
sample size calculations to account for the possibility of
a below-average flu season or studies with longer dur-
ation, e.g., those that include 2 or more influenza sea-
sons to account for lower than predicted attack rates,
are necessary to achieve the desired results [25].
In addition, 10.8 % of enrolled subjects in the inosine
pranobex group reported a medical history of gastrointes-
tinal disorders and 10.4 % reported hepatobiliary disor-
ders. Pharmacokinetic parameters were not measured in
this study, but it is possible that the presence of these dis-
orders at baseline may have affected the absorption, distri-
bution, and metabolism of the study drug and may have
influenced the study results, including the efficacy results.
Furthermore, age, comorbidities, and the obesity of en-
rolled subjects, particularly in subjects more than 50 years
of age, may also have affected the outcome of the study.
The safety analysis demonstrated that inosine prano-
bex treatment was well tolerated, and no major differ-
ences in safety profiles were observed between treatment
groups. Treatment-emergent SAEs were reported in 2
subjects, and none were considered to be related to
study drug by the investigators. No subjects died during
the study. No significant changes were observed in vital
signs and physical examinations in either study group.
Conclusions
The study results indicate the safety of inosine pranobex
for the treatment of subjects with confirmed acute respira-
tory viral infections and confirms the efficacy of inosine
pranobex versus placebo in healthy non-obese subjects
less than 50 years of age with clinically diagnosed
influenza-like illnesses. The results of this study were af-
fected by epidemiologic considerations, which included a
late influenza alert and a low density of circulating viruses.
Further studies may be important to define predictors of
treatment success, including the potential of different dos-
ing strategies in certain patient populations, such as those
with underlying conditions that may impact drug plasma
levels and related drug effects.
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